Charles River Labs (CRL) PT Raised to $322 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $344.87 +9.33%
Rating Summary:
24 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
24 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
RBC Capital analyst Ryan Halsted raised the price target on Charles River Labs (NYSE: CRL) to $322.00 (from $282.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Abbott Labs (ABT) PT Lowered to $125 at BTIG
- Disc Medicine (IRON) PT Raised to $149 at Jefferies
- SpaceX (SPCX) PT Raised to $260 at Pivotal Research
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
